Health Care • Biotechnology: Commercial Physical & Biological Resarch
$12.10 ▲ +0.22
(+1.85%)
MKT CAP: $2.08B • VOL: 4.34M
52W L $2 52W H $13
ROARABLE / RQD
D • 45/100
PIOTROSKI
2 / 9
ABSI // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $4.5M | $5.7M |
| YoY Revenue Growth % | — | -20.7% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$120.3M | -$108.9M | -$115.5M |
| Operating Margin % | — | -80.0% | -80.0% |
| Net Income (GAAP) | -$115.2M | -$103.1M | -$110.6M |
| EBITDA (Normalized) | -$119.4M | -$108.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$92.9M | -$72.4M | -$64.6M |
| Capital Expenditures (CapEx) | $1.1M | $404.0K | — |
| Free Cash Flow (FCF) | -$94.0M | -$72.8M | -$64.6M |
| FCF Margin % | — | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $20.0M | $41.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $189.4M | $179.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ABSI.